Comparative Pharmacology
Head-to-head clinical analysis: ANZUPGO versus LONSURF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANZUPGO versus LONSURF.
ANZUPGO vs LONSURF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not established; no known pharmacological mechanism due to lack of clinical data.
LONSURF (trifluridine and tipiracil) is a combination of the thymidine-based nucleoside analogue trifluridine and the thymidine phosphorylase inhibitor tipiracil. Trifluridine incorporates into DNA and inhibits cell proliferation, while tipiracil increases trifluridine exposure by inhibiting its degradation by thymidine phosphorylase.
Not available. ANZUPGO is not a recognized drug in medical literature.
Adults: 35 mg/m2 orally twice daily on days 1-5 and 8-12 of each 28-day cycle.
None Documented
None Documented
Terminal elimination half-life is 2.5-3.0 hours; clinically, this supports intravenous administration every 6-8 hours for continuous coverage.
Trifluridine: terminal half-life approximately 1.4-2.1 hours; tipiracil: terminal half-life approximately 2-3 hours. Clinical context: short half-lives necessitate twice-daily dosing on Days 1-5 and 8-12 of a 28-day cycle.
Renal excretion of unchanged drug accounts for 70-80%; biliary/fecal elimination constitutes the remainder (20-30%).
Primarily renal: tipiracil is excreted unchanged in urine (approximately 50% of dose); trifluridine is eliminated via metabolism and renal excretion (as metabolites and unchanged drug). Fecal elimination accounts for <3% of total clearance.
Category C
Category C
Antineoplastic
Antineoplastic